SRZN
$25.15-1.48 (-5.56%)
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair.
Recent News
Surrozen Conference: CEO Details Wnt-Fzd4 Eye Disease Bet, 2026 IND Plans for SZN-8141
Surrozen (NASDAQ:SRZN) Chief Executive Officer Craig Parker used a discussion at a 2026 investor summit to outline the company’s focus on Wnt pathway biology and antibody engineering, with an emphasis on retinal vascular diseases. Parker said Surrozen has worked on Wnt signaling since its founding i
We're Hopeful That Surrozen (NASDAQ:SRZN) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Surrozen...
Institutions own 32% of Surrozen, Inc. (NASDAQ:SRZN) shares but private equity firms control 32% of the company
Key Insights Surrozen's significant private equity firms ownership suggests that the key decisions are influenced by...
We Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...